For a biopharmaceutical industry in flux, outsourcing services are playing a greater and more diverse role in drug development.
麻豆原创 Analysis and Insights: Global Outsourcing in Drug Development 麻豆原创
The global Outsourcing in Drug Development market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers:
This report presents an overview of global market for Outsourcing in Drug Development market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Outsourcing in Drug Development, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Outsourcing in Drug Development, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Outsourcing in Drug Development revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Outsourcing in Drug Development market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Outsourcing in Drug Development revenue, projected growth trends, production technology, application and end-user industry.
麻豆原创 Segmentation
By Company
Charles River Laboratories
Covance
ICON
Parexel
Quintiles Transnational
PPD
PRA Health Sciences
Segment by Type
Clinical Trials
New Drug Application
Segment by Application
Pharmaceutical Industries
Biotechnology Industries
Medical Device Industries
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Outsourcing in Drug Development in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Outsourcing in Drug Development companies鈥� competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: China by Type, and by Application, revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Outsourcing in Drug Development revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Outsourcing in Drug Development 麻豆原创 Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Clinical Trials
1.2.3 New Drug Application
1.3 麻豆原创 by Application
1.3.1 Global Outsourcing in Drug Development 麻豆原创 Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Pharmaceutical Industries
1.3.3 Biotechnology Industries
1.3.4 Medical Device Industries
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Outsourcing in Drug Development 麻豆原创 Perspective (2019-2030)
2.2 Global Outsourcing in Drug Development Growth Trends by Region
2.2.1 Outsourcing in Drug Development 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Outsourcing in Drug Development Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Outsourcing in Drug Development Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Outsourcing in Drug Development 麻豆原创 Dynamics
2.3.1 Outsourcing in Drug Development Industry Trends
2.3.2 Outsourcing in Drug Development 麻豆原创 Drivers
2.3.3 Outsourcing in Drug Development 麻豆原创 Challenges
2.3.4 Outsourcing in Drug Development 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Outsourcing in Drug Development by Players
3.1.1 Global Outsourcing in Drug Development Revenue by Players (2019-2024)
3.1.2 Global Outsourcing in Drug Development Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Outsourcing in Drug Development 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Outsourcing in Drug Development, Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global Outsourcing in Drug Development 麻豆原创 Concentration Ratio
3.4.1 Global Outsourcing in Drug Development 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Outsourcing in Drug Development Revenue in 2023
3.5 Global Key Players of Outsourcing in Drug Development Head office and Area Served
3.6 Global Key Players of Outsourcing in Drug Development, Product and Application
3.7 Global Key Players of Outsourcing in Drug Development, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Outsourcing in Drug Development Breakdown Data by Type
4.1 Global Outsourcing in Drug Development Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Outsourcing in Drug Development Forecasted 麻豆原创 Size by Type (2025-2030)
5 Outsourcing in Drug Development Breakdown Data by Application
5.1 Global Outsourcing in Drug Development Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Outsourcing in Drug Development Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Outsourcing in Drug Development 麻豆原创 Size (2019-2030)
6.2 North America Outsourcing in Drug Development 麻豆原创 Size by Type
6.2.1 North America Outsourcing in Drug Development 麻豆原创 Size by Type (2019-2024)
6.2.2 North America Outsourcing in Drug Development 麻豆原创 Size by Type (2025-2030)
6.2.3 North America Outsourcing in Drug Development 麻豆原创 Share by Type (2019-2030)
6.3 North America Outsourcing in Drug Development 麻豆原创 Size by Application
6.3.1 North America Outsourcing in Drug Development 麻豆原创 Size by Application (2019-2024)
6.3.2 North America Outsourcing in Drug Development 麻豆原创 Size by Application (2025-2030)
6.3.3 North America Outsourcing in Drug Development 麻豆原创 Share by Application (2019-2030)
6.4 North America Outsourcing in Drug Development 麻豆原创 Size by Country
6.4.1 North America Outsourcing in Drug Development 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America Outsourcing in Drug Development 麻豆原创 Size by Country (2019-2024)
6.4.3 North America Outsourcing in Drug Development 麻豆原创 Size by Country (2025-2030)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Outsourcing in Drug Development 麻豆原创 Size (2019-2030)
7.2 Europe Outsourcing in Drug Development 麻豆原创 Size by Type
7.2.1 Europe Outsourcing in Drug Development 麻豆原创 Size by Type (2019-2024)
7.2.2 Europe Outsourcing in Drug Development 麻豆原创 Size by Type (2025-2030)
7.2.3 Europe Outsourcing in Drug Development 麻豆原创 Share by Type (2019-2030)
7.3 Europe Outsourcing in Drug Development 麻豆原创 Size by Application
7.3.1 Europe Outsourcing in Drug Development 麻豆原创 Size by Application (2019-2024)
7.3.2 Europe Outsourcing in Drug Development 麻豆原创 Size by Application (2025-2030)
7.3.3 Europe Outsourcing in Drug Development 麻豆原创 Share by Application (2019-2030)
7.4 Europe Outsourcing in Drug Development 麻豆原创 Size by Country
7.4.1 Europe Outsourcing in Drug Development 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Outsourcing in Drug Development 麻豆原创 Size by Country (2019-2024)
7.4.3 Europe Outsourcing in Drug Development 麻豆原创 Size by Country (2025-2030)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Outsourcing in Drug Development 麻豆原创 Size (2019-2030)
8.2 China Outsourcing in Drug Development 麻豆原创 Size by Type
8.2.1 China Outsourcing in Drug Development 麻豆原创 Size by Type (2019-2024)
8.2.2 China Outsourcing in Drug Development 麻豆原创 Size by Type (2025-2030)
8.2.3 China Outsourcing in Drug Development 麻豆原创 Share by Type (2019-2030)
8.3 China Outsourcing in Drug Development 麻豆原创 Size by Application
8.3.1 China Outsourcing in Drug Development 麻豆原创 Size by Application (2019-2024)
8.3.2 China Outsourcing in Drug Development 麻豆原创 Size by Application (2025-2030)
8.3.3 China Outsourcing in Drug Development 麻豆原创 Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Outsourcing in Drug Development 麻豆原创 Size (2019-2030)
9.2 Asia Outsourcing in Drug Development 麻豆原创 Size by Type
9.2.1 Asia Outsourcing in Drug Development 麻豆原创 Size by Type (2019-2024)
9.2.2 Asia Outsourcing in Drug Development 麻豆原创 Size by Type (2025-2030)
9.2.3 Asia Outsourcing in Drug Development 麻豆原创 Share by Type (2019-2030)
9.3 Asia Outsourcing in Drug Development 麻豆原创 Size by Application
9.3.1 Asia Outsourcing in Drug Development 麻豆原创 Size by Application (2019-2024)
9.3.2 Asia Outsourcing in Drug Development 麻豆原创 Size by Application (2025-2030)
9.3.3 Asia Outsourcing in Drug Development 麻豆原创 Share by Application (2019-2030)
9.4 Asia Outsourcing in Drug Development 麻豆原创 Size by Region
9.4.1 Asia Outsourcing in Drug Development 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia Outsourcing in Drug Development 麻豆原创 Size by Region (2019-2024)
9.4.3 Asia Outsourcing in Drug Development 麻豆原创 Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Outsourcing in Drug Development 麻豆原创 Size (2019-2030)
10.2 Middle East, Africa, and Latin America Outsourcing in Drug Development 麻豆原创 Size by Type
10.2.1 Middle East, Africa, and Latin America Outsourcing in Drug Development 麻豆原创 Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America Outsourcing in Drug Development 麻豆原创 Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America Outsourcing in Drug Development 麻豆原创 Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America Outsourcing in Drug Development 麻豆原创 Size by Application
10.3.1 Middle East, Africa, and Latin America Outsourcing in Drug Development 麻豆原创 Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America Outsourcing in Drug Development 麻豆原创 Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America Outsourcing in Drug Development 麻豆原创 Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America Outsourcing in Drug Development 麻豆原创 Size by Country
10.4.1 Middle East, Africa, and Latin America Outsourcing in Drug Development 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America Outsourcing in Drug Development 麻豆原创 Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America Outsourcing in Drug Development 麻豆原创 Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Charles River Laboratories
11.1.1 Charles River Laboratories Company Details
11.1.2 Charles River Laboratories Business Overview
11.1.3 Charles River Laboratories Outsourcing in Drug Development Introduction
11.1.4 Charles River Laboratories Revenue in Outsourcing in Drug Development Business (2019-2024)
11.1.5 Charles River Laboratories Recent Developments
11.2 Covance
11.2.1 Covance Company Details
11.2.2 Covance Business Overview
11.2.3 Covance Outsourcing in Drug Development Introduction
11.2.4 Covance Revenue in Outsourcing in Drug Development Business (2019-2024)
11.2.5 Covance Recent Developments
11.3 ICON
11.3.1 ICON Company Details
11.3.2 ICON Business Overview
11.3.3 ICON Outsourcing in Drug Development Introduction
11.3.4 ICON Revenue in Outsourcing in Drug Development Business (2019-2024)
11.3.5 ICON Recent Developments
11.4 Parexel
11.4.1 Parexel Company Details
11.4.2 Parexel Business Overview
11.4.3 Parexel Outsourcing in Drug Development Introduction
11.4.4 Parexel Revenue in Outsourcing in Drug Development Business (2019-2024)
11.4.5 Parexel Recent Developments
11.5 Quintiles Transnational
11.5.1 Quintiles Transnational Company Details
11.5.2 Quintiles Transnational Business Overview
11.5.3 Quintiles Transnational Outsourcing in Drug Development Introduction
11.5.4 Quintiles Transnational Revenue in Outsourcing in Drug Development Business (2019-2024)
11.5.5 Quintiles Transnational Recent Developments
11.6 PPD
11.6.1 PPD Company Details
11.6.2 PPD Business Overview
11.6.3 PPD Outsourcing in Drug Development Introduction
11.6.4 PPD Revenue in Outsourcing in Drug Development Business (2019-2024)
11.6.5 PPD Recent Developments
11.7 PRA Health Sciences
11.7.1 PRA Health Sciences Company Details
11.7.2 PRA Health Sciences Business Overview
11.7.3 PRA Health Sciences Outsourcing in Drug Development Introduction
11.7.4 PRA Health Sciences Revenue in Outsourcing in Drug Development Business (2019-2024)
11.7.5 PRA Health Sciences Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Charles River Laboratories
Covance
ICON
Parexel
Quintiles Transnational
PPD
PRA Health Sciences
听
听
*If Applicable.
